Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CORT
stocks logo

CORT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
259.98M
+42.93%
0.376
+44.62%
240.75M
+53.14%
0.036
-78.82%
247.75M
+27.42%
0.092
-68.28%
Estimates Revision
The market is revising Downward the revenue expectations for Corcept Therapeutics Incorporated (CORT) for FY2025, with the revenue forecasts being adjusted by -1.47% over the past three months. During the same period, the stock price has changed by 22.06%.
Revenue Estimates for FY2025
Revise Downward
down Image
-1.47%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-7.64%
In Past 3 Month
Stock Price
Go Up
up Image
+22.06%
In Past 3 Month
Wall Street analysts forecast CORT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CORT is 135.33 USD with a low forecast of 121.00 USD and a high forecast of 145.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast CORT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CORT is 135.33 USD with a low forecast of 121.00 USD and a high forecast of 145.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 84.660
sliders
Low
121.00
Averages
135.33
High
145.00
Current: 84.660
sliders
Low
121.00
Averages
135.33
High
145.00
Wolfe Research
Kalpit Patel
Peer Perform
initiated
2025-11-17
Reason
Wolfe Research
Kalpit Patel
Price Target
2025-11-17
initiated
Peer Perform
Reason
Wolfe Research analyst Kalpit Patel initiated coverage of Corcept Therapeutics with a Peer Perform rating and no price target. The firm's analysis of Cushing's syndrome standard of care versus relacorilant and Korlym finds the former may not have the same clinical benefits as the latter, the analyst tells investors.
Canaccord
Buy
maintain
$137 -> $140
2025-09-10
Reason
Canaccord
Price Target
$137 -> $140
2025-09-10
maintain
Buy
Reason
Canaccord raised the firm's price target on Corcept Therapeutics to $140 from $137 and keeps a Buy rating on the shares. The firm met with management and updated its model to reflect the company's distribution fix and its oncology commercial infrastructure that they are building out to include the EU as well.
Canaccord
Edward Nash
Buy
downgrade
$142 -> $137
2025-08-01
Reason
Canaccord
Edward Nash
Price Target
$142 -> $137
2025-08-01
downgrade
Buy
Reason
Canaccord analyst Edward Nash lowered the firm's price target on Corcept Therapeutics to $137 from $142 and keeps a Buy rating on the shares. The firm noted they reported financial results and business highlights for 2Q25. Korlym product sales revenue was $194.4M for the quarter, slightly higher than the firm's estimate of $193M, representing an 18.7% Y/Y growth.
Piper Sandler
David Amsellem
Overweight
downgrade
$131 -> $121
2025-08-01
Reason
Piper Sandler
David Amsellem
Price Target
$131 -> $121
2025-08-01
downgrade
Overweight
Reason
Piper Sandler analyst David Amsellem lowered the firm's price target on Corcept Therapeutics to $121 from $131, owing mainly to slightly lower Korlym estimates and higher SG&A estimates, while keeping an Overweight rating on the shares. The firm notes Corcept reported Q2 diluted EPS of 29c on revenue of $194M, compared to Street estimates of 19c and $199M, respectively.
Piper Sandler
David Amsellem
Buy
Maintains
$128 → $131
2025-04-03
Reason
Piper Sandler
David Amsellem
Price Target
$128 → $131
2025-04-03
Maintains
Buy
Reason
Piper Sandler raised the firm's price target on Corcept Therapeutics to $128 from $78 and keeps an Overweight rating on the shares.
Canaccord Genuity
Edward Nash
Strong Buy
Maintains
$130 → $142
2025-04-01
Reason
Canaccord Genuity
Edward Nash
Price Target
$130 → $142
2025-04-01
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Corcept Therapeutics Inc (CORT.O) is 109.38, compared to its 5-year average forward P/E of 32.74. For a more detailed relative valuation and DCF analysis to assess Corcept Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Overvalued
5Y Average PE
32.74
Current PE
109.38
Overvalued PE
49.14
Undervalued PE
16.35

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
18.84
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
25.16
Undervalued EV/EBITDA
12.53

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
6.12
Current PS
0.00
Overvalued PS
7.49
Undervalued PS
4.75
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

CORT News & Events

Events Timeline

(ET)
2025-11-04
16:41:34
Corcept Therapeutics Announces Q3 Earnings Per Share of 16 Cents, Exceeding Consensus Estimate of 14 Cents
select
2025-10-14 (ET)
2025-10-14
08:05:09
Corcept Files Marketing Authorization Application for Relacorilant with EMA
select
2025-10-10 (ET)
2025-10-10
12:00:29
Corcept Therapeutics Experiences a 13.3% Decline
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.0
02:00 AMNASDAQ.COM
Significant Options Trading on Thursday: WBD, CALM, CORT

  • Cal-Maine Foods Options Activity: Cal-Maine Foods Inc (CALM) has seen a trading volume of 3,859 options contracts today, representing about 49.7% of its average daily trading volume, with significant activity in the $100 strike call option expiring January 16, 2026.

  • Corcept Therapeutics Options Activity: Corcept Therapeutics Inc (CORT) has recorded a volume of 3,240 options contracts today, which is approximately 49.5% of its average daily trading volume, with notable trading in the $60 strike put option expiring January 16, 2026.

  • Options Trading Insights: The article highlights the trading history of CALM and CORT options, indicating a trend in high-volume contracts for specific strike prices.

  • Source Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.

[object Object]
Preview
9.5
11-28NASDAQ.COM
Corcept (CORT) Third Quarter 2025 Earnings Call Summary
  • Author's Perspective: The views and opinions presented are solely those of the author.
  • No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
[object Object]
Preview
9.0
11-27NASDAQ.COM
Biotech Stocks Await FDA Verdict in December 2025

  • National Influenza Vaccination Week: Observed from December 1-5, this campaign encourages vaccination against the flu, emphasizing its safety and effectiveness, and serves as a reminder that it's never too late to get vaccinated.

  • World AIDS Day: Celebrated on December 1, this global observance raises awareness about HIV/AIDS, honors those lost, and supports those living with the virus, with a focus on political leadership and human rights to end AIDS as a public health threat by 2030.

  • HIV Statistics: In 2024, approximately 40.8 million people were living with HIV, with around 630,000 deaths from HIV-related causes and 1.3 million new infections, highlighting the ongoing impact of the epidemic.

  • Funding Concerns: There are worries about significant cuts to international HIV funding, particularly from the U.S., which has historically contributed nearly 75% of global financing, with recent reductions affecting key commitments and activities related to World AIDS Day.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Corcept Therapeutics Inc (CORT) stock price today?

The current price of CORT is 84.66 USD — it has increased 1.18 % in the last trading day.

arrow icon

What is Corcept Therapeutics Inc (CORT)'s business?

Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.

arrow icon

What is the price predicton of CORT Stock?

Wall Street analysts forecast CORT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CORT is 135.33 USD with a low forecast of 121.00 USD and a high forecast of 145.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Corcept Therapeutics Inc (CORT)'s revenue for the last quarter?

Corcept Therapeutics Inc revenue for the last quarter amounts to 207.64M USD, increased 13.75 % YoY.

arrow icon

What is Corcept Therapeutics Inc (CORT)'s earnings per share (EPS) for the last quarter?

Corcept Therapeutics Inc. EPS for the last quarter amounts to 0.16 USD, decreased -61.90 % YoY.

arrow icon

What changes have occurred in the market's expectations for Corcept Therapeutics Inc (CORT)'s fundamentals?

The market is revising Downward the revenue expectations for Corcept Therapeutics Incorporated (CORT) for FY2025, with the revenue forecasts being adjusted by -1.47% over the past three months. During the same period, the stock price has changed by 22.06%.
arrow icon

How many employees does Corcept Therapeutics Inc (CORT). have?

Corcept Therapeutics Inc (CORT) has 500 emplpoyees as of December 05 2025.

arrow icon

What is Corcept Therapeutics Inc (CORT) market cap?

Today CORT has the market capitalization of 8.91B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free